Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.69 -0.81 (-1.71%)
Official Closing Price Updated: 4:10 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
Price Over Earnings Overview: Bristol-Myers Squibb
 
Via Benzinga
What Analysts Are Saying About Bristol-Myers Squibb Stock
 
Via Benzinga
Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary
Warren Buffett is indirectly invested in high-dividend yield stocks via Berkshire Hathaway Inc.'s subsidiary New England Asset Management. 
Via Benzinga
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch.
Via The Motley Fool
Topics ETFs Regulatory Compliance
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
Is Pfizer Stock a Yield Trap?
Via The Motley Fool
Topics Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
3 Large-Cap Stocks Skating on Thin Ice
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors. 
Via Chartmill
FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers
FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements. 
Via Benzinga
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
From Bristol Myers Squibb
Via Business Wire
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drug
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst. 
Via Benzinga
Topics Fraud Lawsuit
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Stock Worth Considering
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers strong profitability, a high dividend yield, and an attractive valuation, making it a potential pick for value investors. 
Via Chartmill
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol Myers’ Cancer Drug Data Fuels Retail Buzz, But Bearish Sentiment Lingers
The new data showed that its lymphoma therapy, Breyanzi, delivered a 95.5% response rate and strong 24-month survival outcomes in a Phase 2 trial. 
Via Stocktwits
Top S&P500 movers in Monday's session
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
From Bristol Myers Squibb
Via Business Wire
2 Beaten-Down Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Economy World Trade
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline. 
Via Benzinga
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.